Publications by authors named "K Ohnaka"
Background/objectives: There is a notable lack of evidence regarding the long-term effects of rehabilitation services, particularly concerning functional recovery and daily living activities of patients following discharge from convalescent rehabilitation wards. This study aimed to clarify the longitudinal changes in activities of daily living and instrumental activities of daily living of patients after discharge from a convalescent rehabilitation ward and the association between the use of rehabilitation services and clinical outcomes.
Methods: Patients discharged from Japanese convalescent rehabilitation wards in August 2021 were included.
Tumor-induced osteomalacia (TIO) is an acquired fibroblast growth factor 23 (FGF23)-related hypophosphatemic osteomalacia caused by phosphaturic mesenchymal tumors (PMTs) developed in the bone or soft tissue. Diagnostic delay should be addressed, and ideal techniques to localize PMTs and efficient treatment options should be explored to improve the outcomes of this rare disease. To clarify the detailed clinical course and outcomes of TIO patients, retrospective questionnaire surveys were conducted among physicians from the Japanese Society for Bone and Mineral Research (JSBMR) and the Japan Endocrine Society (JES).
View Article and Find Full Text PDFAim: To evaluate the effects of an intensity display type accelerometer on diabetic patients' physical activity.
Methods: This was a two-arm, non-randomized controlled study. Both groups received information about the recommendation of 150 min/week moderate-to-vigorous physical activity (MVPA).
Objective: The first ever genome-wide association study (GWAS) of clinically defined gout cases and asymptomatic hyperuricaemia (AHUA) controls was performed to identify novel gout loci that aggravate AHUA into gout.
Methods: We carried out a GWAS of 945 clinically defined gout cases and 1003 AHUA controls followed by 2 replication studies. In total, 2860 gout cases and 3149 AHUA controls (all Japanese men) were analysed.
Article Synopsis
- A case study of a 50-year-old woman with malignant melanoma revealed that her chronic adrenal insufficiency worsened during ipilimumab treatment, necessitating hydrocortisone therapy, while her condition did not require corticosteroids during later nivolumab treatment.
- The findings suggest that different immune mechanisms of ipilimumab and nivolumab may influence patient outcomes and highlight the need for careful glucocorticoid management in patients on ipilimumab.